Spot on with this excerpt - ‘In “traditional” drug development, this is pretty standard. But for most biotech startups, this is what makes them unique. Their secret sauce, if you will. So of course off-the-shelf software isn’t going to reflect this part of their workflow model’
This is where services and implementations come in. Most LIMs companies will provide an OOTB solution that gets you 60-80% there.
Yeah, I think that other 20-40% is more or less unavoidable. There's a lot of talk about service-oriented vs product-oriented companies, but I don't know if you can completely get away from services. (I know some folks are trying hard, though.)
Spot on with this excerpt - ‘In “traditional” drug development, this is pretty standard. But for most biotech startups, this is what makes them unique. Their secret sauce, if you will. So of course off-the-shelf software isn’t going to reflect this part of their workflow model’
This is where services and implementations come in. Most LIMs companies will provide an OOTB solution that gets you 60-80% there.
Yeah, I think that other 20-40% is more or less unavoidable. There's a lot of talk about service-oriented vs product-oriented companies, but I don't know if you can completely get away from services. (I know some folks are trying hard, though.)